SciELO - Scientific Electronic Library Online

vol.31 número6Ação protetora de deferiprona e desferoxamina nos eritrócitos isolados de pacientes com β-talassemiasCaracterísticas genéticas da leucemia promielocítica aguda de novo índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados


Revista Brasileira de Hematologia e Hemoterapia

versão impressa ISSN 1516-8484


LOPES, Nei R.  e  ABREU, Maria Theresa C. L.. Tyrosine kinase inhibitors in chronic myeloid leukemia. Rev. Bras. Hematol. Hemoter. [online]. 2009, vol.31, n.6, pp.449-453.  Epub 11-Dez-2009. ISSN 1516-8484.

Chronic myeloid leukemia (CML) is a neoplastic transformation of the hematopoietic system resulting from a t(9;22)(q34;q11) translocation forming a BCR-ABL hybrid gene which has intense enzyme tyrosine kinase activity responsible for the proliferation of tumor cells. A dramatic positive response was achieved in CML patients with imatinib. This drug is effective in most patients because it presents long-lasting responses. However, some patients are resistant or develop resistance during treatment, particularly in the late-stage disease, thus second generation tyrosine kinase inhibitors such as dasatinib and nilotinib were developed to reduce the risk of developing resistance. Bosutinib and INNO-406 are being developed to treat resistant patients and also to reduce the side effects of the aforementioned drugs. Additionally, novel tyrosine kinase inhibitors are in clinical or preclinical development stages. In the future, multiple treatment options will be available for patients with CML, with the possibility to individualize the treatment according to the needs of each patient. In the current study we describe antineoplastic drugs that act as tyrosine kinase enzyme inhibitors in CML.

Palavras-chave : Tyrosine kinase; chronic myeloid leukemia; therapy.

        · resumo em Português     · texto em Português     · Português ( pdf )


Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons